Dr. Gwan Sun Lee, Chief Executive Officer of Hanmi Pharmaceuticals states: "This collaboration is an important strategic decision for Hanmi Pharmaceuticals as this will facilitate our company to further expand our oncology franchise to China and other Asian Countries."
Dr. Jeewoong Son, Chief Medical Officer and Senior Vice-President of Research and Development, states: "The profile of KX01 is excellent and this compound will complement our oncology business strategy very well. We are excited to have the opportunity to work with the Kinex team to take this compound through the various development phases to obtain its approval in Korea and China to help Asian patients with cancer."
Hanmi Pharmaceuticals is one of leading pharmaceutical companies in Korea. Hanmi Pharmaceuticals has established a strong Research and Development team in Korea and one of their focuses is in the field of oncology.
"We have selected Hanmi Pharmaceuticals as our Asian partner because we are impressed by their strong commitment to Research and Development. We are also impressed by their business growth strategy", states Chief Executive Officer of Kinex Pharmaceuticals, Dr. Allen Barnett, who was credited for his effort in the discovery and development of Claritin when he was working at the Schering-Plough Research Institute.
Dr. David Hangauer, Senior Vice-President of Research and Development states: "Kinex Pharmaceuticals is delighted to have a chance to work with this well established research and development team. Their experience in oncology will be critical in helping to drive this project to regulatory approval."
"We are impressed by the clinical research commitments of Hanmi Pharmaceuticals. Together with our internal programs, we are confident that our joint effort will expedite the realization of the full potential of KX01," states Chief Medical Officer of Kinex Pharmaceuticals,
|SOURCE Kinex Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved